Gyre Therapeutics GYRE
$4.76 +$0.75 (+18.70%)
Market closed · Nov 6, 8:10 pm ET · Last extended-hours $4.76 0.00%
Open$4.56
Prev close$4.01
Day range$4.08 – $4.79
Volume359.7K
Market cap$504.72M
P/E (TTM)–
Dividend yield–
GYRE Stock News
Headlines matching Gyre Therapeutics or the GYRE ticker, most recent first.
- GNI Group: Gyre Therapeutics to Participate in U.S. Healthcare Conferences
- GNI Group: Regarding Gyre Therapeutics' Participation in the U.S. Healthcare Conference
- H.C. Wainwright Sticks to Its Buy Rating for Gyre Therapeutics (GYRE)
- GNI Group: Notice Regarding the Release of Corporate Presentation Materials by Consolidated Subsidiary Gyre Therapeutics, Inc.
- Noble Financial Maintains Gyre Therapeutics(GYRE.US) With Buy Rating, Maintains Target Price $20
- Gyre Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Epstein David M.
- GNI Group: Notice Regarding the Release of Corporate Presentation Materials by Consolidated Subsidiary Gyre Therapeutics, Inc.
- Gyre Therapeutics Shares Are Trading Lower After the Company Reported Worse-than-expected Q1 Sales Results.
- Gyre Therapeutics Q1 Adj. EPS $(0.04) Beats $(0.07) Estimate, Sales $22.519M Miss $31.607M Estimate Mixed
- Gyre Therapeutics Q4 Adj. EPS $0.05 Misses $0.06 Estimate, Sales $37.195M Beat $36.303M Estimate Mixed
- H.C. Wainwright Maintains Gyre Therapeutics(GYRE.US) With Buy Rating, Maintains Target Price $18
- H.C. Wainwright Initiates Gyre Therapeutics(GYRE.US) With Buy Rating, Announces Target Price $18
- TR | OpenAI - 4o Maintains Gyre Therapeutics(GYRE.US) With Hold Rating, Raises Target Price to $8.5 Positive
- H.C. Wainwright Initiates Gyre Therapeutics(GYRE.US) With Buy Rating, Announces Target Price $25
- H.C. Wainwright Initiates a Buy Rating on Gyre Therapeutics (GYRE)
No comments yet — be the first to weigh in on GYRE.